Pasithea Therapeutics
KTTA
25 hedge funds and large institutions have $8.66M invested in Pasithea Therapeutics in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 0 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
19% more funds holding
Funds holding: 21 → 25 (+4)
11.8% more ownership
Funds ownership: 55.51% → 67.31% (+12%)
9% less capital invested
Capital invested by funds: $9.52M → $8.66M (-$854K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.41M |
| 2 |
CCC
Cable Car Capital
San Francisco,
California
|
+$1.23M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$943K |
| 4 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$413K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$353K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.12M |
| 2 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
-$757K |
| 3 |
Renaissance Technologies
New York
|
-$19.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$13.8K |
KTTA Hedge Fund Activity: Q2 2026 in Review
25 of the 8,323 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q2 2026, worth a combined $8.66M — down 9% from $9.52M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new KTTA positions and 0 closed out — a net gain of 5 holders — while 11 added to existing stakes and 4 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $1.41M. The largest seller was Vivo Capital, cutting an estimated $1.12M.
- 25 institutional investors held Pasithea Therapeutics (KTTA) as of Q2 2026, up from 21 in Q1 2026.
- Funds reported $8.66M of Pasithea Therapeutics stock for Q2 2026, down 9% quarter-over-quarter.
- 5 funds opened new Pasithea Therapeutics positions in Q2 2026 and 0 closed out, a net change of +5 holders.
- The largest Pasithea Therapeutics buyer in Q2 2026 was Opaleye Management, an estimated $1.41M added.
- The largest Pasithea Therapeutics seller in Q2 2026 was Vivo Capital, an estimated $1.12M sold.
Based on aggregated 13F filings for Q2 2026.